6 Dimensions Capital was established in May, 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures. The two prominent and experienced teams formed a healthcare focused investment firm with an in-depth focus and extensive coverage both in China and global market.

6 Dimensions Capital

Delta Capital Management, LLC is a Memphis-based venture capital firm founded in 1992 that manages over $90 million in venture capital allocations from institutional investors and high net worth individuals through several partnerships. We invest primarily in early and expansion stage companies in the five-state region of Alabama, Arkansas, Louisiana, Mississippi and Tennessee. The firm also considers later stage opportunities across the broader southeastern U.S.  Delta is actively managing two venture capital funds, Delta Venture Partners I, L.P. and Delta Venture Partners II, L.P., which total over $60 million.  The firm focuses on several industries that have a meaningful presence in Delta's region and where the firm's partners have significant experience:   * Health Care  * Information * Technology * Supply Chain * Logistics * Business Services * Industrial Technology * Energy Technology  While most of Delta's investment activities will focus on these industries, we may also invest in other industries where an attractive opportunity exists. We assist our portfolio companies in their strategic planning, management development, financing and then exit our investments through initial public offerings, strategic sales or recapitalizations.

Delta Capital Management

Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology).   Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.   For more information visit: www.windhamvp.com

Windham Venture Partners

GlaxoSmithKline today announced the launch of Action Potential Venture Capital (APVC) Limited, a new $50 million strategic venture capital fund that will invest in companies that pioneer bioelectronic medicines and technologies.   The fund’s first investment will be in SetPoint Medical, a California company considered a trailblazer in creating implantable devices to treat inflammatory diseases.  The fund complements the work of GSK’s Bioelectronics R&D unit, which was established in 2012 after a two-year effort to seek out and engage the most promising researchers in this emerging area of science.   The name of the fund comes from electrical signals called action potentials that pass along the nerves in the body. Irregular or altered patterns of these impulses may occur in association with a broad range of diseases.   GSK believes that miniaturised devices, or bioelectronic medicines, can be designed to read these patterns. The devices could be designed to interface between the peripheral nervous system and specific organs to read, change or generate electronic impulses that help treat disorders as diverse as inflammatory bowel disease or rheumatoid arthritis; respiratory diseases such as asthma and COPD and metabolic diseases including Type 2 diabetes.  The field of bioelectronic medicines is in its very early stages. GSK’s ambition, through collaboration with scientists globally, is to have the first medicine that speaks the electrical language of our body ready for approval by the end of this decade.“We want to help create the medicines of the future and be the catalyst for this work,” said Moncef Slaoui, chairman of R&D and architect of GSK’s early stage investment strategy. “GSK can play the integrating role that is needed to drive this new type of medical treatment all the way from the bench to the patient and this fund is a key part of our efforts.”  Action Potential Venture Capital intends to build a portfolio of five to seven companies over the next five years. The fund will focus investments in three areas:  - New start-up companies that aim to pursue the vision of bioelectronic medicines - Existing companies with technologies that are interacting with the peripheral nervous system  through first-generation devices that can stimulate or block electrical impulses - Companies advancing technology platforms that will underpin these treatment modalities  Action Potential Venture Capital will be based in Cambridge, Massachusetts and managed by a small, dedicated team. The fund has named Imran Eba as its first partner. Imran will move from GSK’s Worldwide Business Development organisation and work closely with the Bioelectronics R&D unit.

Action Potential Venture Capital

Alumni Ventures Group provides high-quality, diversified venture portfolios to individual investors who previously haven't had access to VC. It helps accredited alums from top entrepreneurial schools invest together in the ventures of fellow alums. The firm backs companies with an alumni connection and an institutional lead investor with expertise in the space. AVG also offers focused funds that allow any accredited investor access to a venture portfolio, diversified by type, sector, stage, and geography. Beth Obermiller, Michael Madden, and Mike Collins co-founded the firm in Manchester, New Hampshire in 2013.

Alumni Ventures

Vertex Ventures HC invests in various sectors of the healthcare industry, including biopharmaceuticals, medical devices and digital health. Their portfolio includes companies at all stages of development, from early-stage companies testing transformative technologies to commercial-stage companies seeking additional growth. With a focus on areas with significant unmet need, Vertex seeks to build great companies that improve the health and quality of human life. They take an active role in our portfolio companies and work with exceptional entrepreneurs, industry partners and fellow venture investors to create value. Their global investment professionals bring deep scientific, medical and business knowledge to every investment they make.

Vertex Ventures HC

The S.H.I.P. team brings more than 50 years of cumulative healthcare experience in investing and operational roles. We have invested globally in more than 60 companies through multiple market cycles. We worked together on a number of healthcare investments over the last 12 years prior to forming S.H.I.P.  We bring a unique set of investing experiences from one of the largest strategic healthcare funds JJDC, which maintains a portfolio of over $1B and annually invests more than $200 million in medical devices, biotech, and consumer health, and private venture investing experiences at Synergy Life Science Partners, a top quartile performing venture capital fund. The S.H.I.P. team has been involved in some of the premium healthcare companies bringing novel technologies to market.

Treo Ventures

Olympus manufactures and sells precision machinery and instruments. They provide medical systems, medical systems services, life science solutions, and industrial solutions. Their life science solutions provide biological microscope systems including laser scanning microscopes, disk confocal microscopes, and virtual slide microscopes.

Olympus

NeuSpera Medical

NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain

NeuSpera Medical is a medical device company focused on developing implantable neuromodulation devices to treat patients suffering from chronic illnesses. The company's flagship product, the Nuvella system, is an ultra-miniaturized sacral neuromodulation (SNM) device designed to treat overactive bladder (OAB) with urinary urgency incontinence (UUI) symptoms.

Electroceuticals startup NeuSpera raises $8M to back tiny, injectable neuromodulation tech

FDA approves Neuspera ultra-miniaturised system for peripheral nerve pain

NEUSPERA MEDICAL® ANNOUNCES SECOND PHASE OF SANS-UUI IDE CLINICAL TRIAL WITH THE NUVELLA™ SYSTEM

FDA clears Neuspera Medical peripheral nerve stim

Neuspera Medical, Inc. Completes Patient Enrollment and Implants for the SANS

NEUSPERA MEDICAL® ANNOUNCES FDA CLEARANCE OF ITS SYSTEM FOR PERIPHERAL NERVE STIMULATION

NEUSPERA MEDICAL® ANNOUNCES FIRST SUCCESSFUL IMPLANT OF THE NUVELLA™ SYSTEM IN THE SECOND PHASE OF ITS SANS-UUI IDE CLINICAL TRIAL

Neuspera Medical® announces first successful implant of the Nuvella™ System in the second phase of its sans

Neuspera Announces Leadership Expansion with the Addition of New CMO

Neuspera Medical® Announces FDA Clearance of its System for Peripheral Nerve Stimulation

Phase 2 study of SNM device for UUI meets enrollment goal

Transforming neurological care with innovation

Neurostimulation Tech

Neuspera Medical Closes Series D Funding Round

NeuSpera Medical is a medical device company focused on developing implantable neuromodulation devices to treat patients suffering from chronic illnesses. The company's flagship product, the Nuvella system, is an ultra-miniaturized sacral neuromodulation (SNM) device designed to treat overactive bladder (OAB) with urinary urgency incontinence (UUI) symptoms.
The Nuvella system delivers neuromodulation therapy wirelessly through a micro-implant that is 75 times smaller than the smallest commercial implantable pulse generator. This miniaturized design allows for a less invasive and more adaptable treatment approach, potentially enhancing the patient experience and procedural flexibility for physicians. The system includes a wearable transmitter and an iPad-based clinician programmer.
In May 2023, the company received FDA clearance for its next-generation Neuspera ultra-miniaturized system, designed for peripheral nerve stimulation (PNS) in managing chronic peripheral nerve pain. This system operates on a similar wireless platform as the Nuvella device.
NeuSpera Medical has conducted clinical trials to evaluate the safety and efficacy of the Nuvella system. In the feasibility phase of the SANS-UUI study, involving 34 patients implanted with the device, 90% demonstrated at least a 50% improvement in UUI symptoms at six and 12 months with two hours of daily stimulation, while 52% were completely dry at the 12-month visit. The company completed enrollment and implant procedures for the pivotal phase of the SANS-UUI trial in December 2023, with final results expected in the first half of 2024.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Charco Neurotech

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

NeuSpera Medical

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless